Hostname: page-component-848d4c4894-nmvwc Total loading time: 0 Render date: 2024-07-03T13:23:12.217Z Has data issue: false hasContentIssue false
  • English
  • Français

Anticholinergic-neuroleptic antagonism in terms of positive and negative symptoms of schizophrenia: implications for psychobiological subtyping

Published online by Cambridge University Press:  09 July 2009

Man Mohan Singh ,
Stanley R. Kay  and
Lewis A. Opler
Man Mohan Singh*
Affiliation:
Schizophrenia Research Program, Springfield, Illinois, Department of Psychiatry, Albert Einstein College of Medicine, New York, USA.
Stanley R. Kay
Affiliation:
Schizophrenia Research Program, Springfield, Illinois, Department of Psychiatry, Albert Einstein College of Medicine, New York, USA.
Lewis A. Opler
Affiliation:
Schizophrenia Research Program, Springfield, Illinois, Department of Psychiatry, Albert Einstein College of Medicine, New York, USA.
*
1Address for correspondence: Dr M. M. Singh, Schizophrenia Research Program, 901 Southwind Road, Springfield, Illinois 62703, USA.
Get access Rights & Permissions [Opens in a new window]

Synopsis

In three studies of comparable design, 47 schizophrenics received anticholinergic anti-Parkinsonism (AP) medications for two to four weeks along the course of neuroleptic treatment. Clinical ratings during the AP phase were contrasted against the preceding and following two-week periods on neuroleptic alone, and these changes were analysed for a total of 27 psychopathology dimensions and for clusters of seven positive and seven negative symptoms. Schizophrenics overall exhibited significant exacerbation of total psychopathology, and positive but not negative symptoms. Only those with a predominantly positive syndrome when drug-free were susceptible to AP therapeutic reversal. However, other subgroup analyses revealed worsening of total psychopathology and positive symptoms among catatonic, schizophreniform, chronic, and good outcome cases, but negative symptoms alone were significantly increased among paranoids. The results were not supportive of a positive–negative dichotomy of schizophrenia, but instead suggested a tripartite model: a distinct paranoid group and a division of the non-paranoids into a positive and a negative type.

Type
Research Article
Information
Psychological Medicine , Volume 17 , Issue 1 , February 1987 , pp. 39 - 48
Copyright
Copyright © Cambridge University Press 1987

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

American Psychiatric Association (1980). Diagnostic and Statistical Manual of Psychiatric Disorders (3rd edn). APA: Washington, D.C.Google Scholar
Angrist, B, Rotrosen, J & Gershon, S. (1980). Differential effects of amphetamines and neuroleptics on negative v. positive symptoms in schizophrenia. Psychopharmacology 72, 17–19.CrossRefGoogle Scholar
Brown, G. W (1960). Length of hospital stay and schizophrenia: A review of statistical studies. Acta Psychiatrica et Neurologica Scandinavica 35, 414–430.CrossRefGoogle Scholar
Crow, T. J. (1980). Positive and negative schizophrenic symptoms and the role of dopamine. British Journal of Psychiatry 137, 383–386.CrossRefGoogle ScholarPubMed
Crow, T. J., Owens, F., Cross, A. J., Ferrier, I. N., Johnstone, E. C., McCreadie, R. G., Owens, D. G. C. & Poulter, M. (1981). Neurotransmitter enzymes and receptors in post-mortem brain in schizophrenia: Evidence that an increase in D2 dopamine receptors is associated with Type I syndrome. In Transmitter Biochemistry of Human Brain Tissue (ed. Reiderer, P. and Usdin, E.). pp. 85–96. Macmillan: London.CrossRefGoogle Scholar
Davis, J. M., Janowsky, D. & Casper, R. C. (1977). Acetylcholine and mental disease. In Neuroregulators and Psychiatric Disorders (ed. Usdin, E., Hamburg, D. and Barchas, J.), pp. 434–441. Oxford University Press: New York.Google Scholar
Haase, H. (1962). Intensity and equivalence of neuroleptic effect and its therapeutic importance. Nervenarzt 33, 213–220.Google ScholarPubMed
Horvath, T. & Meares, R. (1979). The sensory filter in schizophrenia: a study of habituation, arousal and dopamine hypothesis. British Journal of Psychiatry 134, 39–45.CrossRefGoogle ScholarPubMed
Johnstone, E. C., Crow, T. J., Ferrier, I. N., Frith, C. D., Owens, D. G. C., Bourne, R. C. & Gamble, S. J. (1983). Adverse effects of anticholinergic medication on positive schizophrenic symptoms. Psychological Medicine 13, 513–527.CrossRefGoogle ScholarPubMed
Johnstone, E. C., Crow, T. J., Frith, C. D., Carney, M. W. P. & Price, J. S. (1978). Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet i, 848–851.CrossRefGoogle Scholar
Kammen, D. P. van & Antelman, S (1984). Impaired noradrenergic transmission in schizophrenia? Life Sciences 34, 1403–1413.CrossRefGoogle ScholarPubMed
Kay, S. R. (1982). Conceptual disorder in schizophrenia as a function of encoding orientation. Journal of Nervous and Mental Disease 170, 154–163.CrossRefGoogle ScholarPubMed
Kay, S. R. & Singh, M. M. (1974). A temporal measure of attention in schizophrenia and its clinical significance. British Journal of Psychiatry 125, 146–151.CrossRefGoogle ScholarPubMed
Kay, S. R. & Singh, M. M. (1975 a). Pulse rate and sleeplessness in relation to nosological distinctions in schizophrenia. Perceptual and Motor Skills 40, 178.CrossRefGoogle ScholarPubMed
Kay, S. R. & Singh, M. M. (1975 b). A developmental approach to delineate components of cognitive dysfunction in schizophrenia. British Journal of Social and Clinical Psychology 14, 387–399.CrossRefGoogle ScholarPubMed
Kay, S. R. & Singh, M. M. (1979). Cognitive abnormality in schizophrenia: A dual-process model. Biological Psychiatry 14, 155–176.Google ScholarPubMed
Kay, S. R., Opler, L. A. and Fiszbein, A. (1986). Significance of positive and negative syndromes in chronic schizophrenia. British Journal of Psychiatry 148 (in the press).Google Scholar
Lake, C. R., Sternberg, D. E., Kammen, D. P. van, Ballenger, J. C., Ziegler, M. G., Post, R. M., Kopin, I. J. & Bunney, W. E. Jr, (1980). Schizophrenia: elevated cerebrospinal fluid norepinephrine. Science 207, 331–333.CrossRefGoogle ScholarPubMed
Langfeldt, G. (1939). Schizophreniform States: A Katamnestic Study Based on Individual Re-examinations. Humphrey Milford: London.Google Scholar
Lindenmayer, J. P., Kay, S. R. & Friedman, C. (1986). Negative and positive schizophrenic syndromes after the acute phase: a prospective follow-up. Comprehensive Psychiatry 27, 276–286.CrossRefGoogle ScholarPubMed
Lindenmayer, J. P., Kay, S. R. & Opler, L. A. (1984). Positive and negative syndromes in young acute schizophrenics. Comprehensive Psychiatry, 25, 455–464.CrossRefGoogle Scholar
Magaro, P. A. & Chamrad, D. L. (1983). Hemispheric preference of paranoid and nonparanoid schizophrenics Biological Psychiatry 18, 1269–1285.Google ScholarPubMed
Mitsuda, H. (1965). The concept of ‘atypical psychoses’ from the aspect of clinical genetics. Acta Psychiatrica Scandinavica 41, 373–377.CrossRefGoogle ScholarPubMed
Opler, L. A., Kay, S R, Rosado, V. & Lindenmayer, J. P. (1984). Positive and negative syndromes in chronic schizophrenic inpatients. Journal of Nervous and Mental Disease 172, 317–325.CrossRefGoogle ScholarPubMed
Overall, J. E. & Gorham, D. R. (1962). Brief psychiatric rating scale. Psychological Reports 10, 799–812.CrossRefGoogle Scholar
Potkin, S. G., Karoum, F., Chuang, L.-W., Cannon-Spoor, H. E., Philips, I. & Wyatt, R. J. (1979). Phenylethylamine in paranoid chronic schizophrenia. Science 206, 470–471.CrossRefGoogle ScholarPubMed
Shakow, D. (1977). Schizophrenia, Selected Papers. Psychology Issues 10, No 2, Monograph No. 38. International Universities Press: New York.Google Scholar
Singh, M. M. & Kay, S. R. (1975 a). A comparative study of haloperidol and chlorpromazine in terms of clinical effects and therapeutic reversal with benztropine in schizophrenia: Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 43, 103–113.CrossRefGoogle ScholarPubMed
Singh, M. M. & Kay, S. R. (1975 b). A longitudinal therapeutic comparison between two prototypic neuroleptics (haloperidol and chlorpromanine) in matched groups of schizophrenics. Nontherapeutic interactions with trihexyphenidyl. Theoretical implications for potency differences among neuroleptics. Psychopharmacologia 43, 115–123.CrossRefGoogle ScholarPubMed
Singh, M. M. & Kay, S. R. (1975 c). Therapeutic reversal with benztropine in schizophrenics: Practical and theoretical significance. Journal of Nervous and Mental Disease 160, 258–266.CrossRefGoogle ScholarPubMed
Singh, M. M. & Kay, S. R. (1976). Wheat gluten – schizophrenia findings. Science 194, 449–450.CrossRefGoogle Scholar
Singh, M. M. & Kay, S. R. (1978 a). Nosological and prognostic distinctions in schizophrenia: Pharmacological validation in terms of therapeutic antagonism between anticholinergic anti-Parkinsonism drugs and neuroleptics. Neuropsychobiology 4, 288–304.CrossRefGoogle ScholarPubMed
Singh, M. M. & Kay, S. R. (1978 b). Therapeutic antagonism between anticholinergics and neuroleptics: Possible involvement of cholinergic mechanisms in schizophrenia. Schizophrenia Bulletin 4, 3–6.CrossRefGoogle Scholar
Singh, M. M. & Kay, S. R. (1979 a). Therapeutic antagonism between anticholinergic anti-Parkinsonism agents and neuroleptics in schizophrenia: Implications for a neuropharmacological model. Neuropsychobiology 5, 74–86.CrossRefGoogle Scholar
Singh, M. M. & Kay, S. R. (1979 b). Dysphoric response to neuroleptic treatment in schizophrenia: its relationship to autonomic arousal and prognosis. Biological Psychiatry 14, 277–294.Google ScholarPubMed
Singh, M. M. & Kay, S. R. (1982). Towards a psychobiological model of schizophrenia: A clinical neuroscientist's view. In Psychobiology of Schizophrenia (ed. Namba, N. and Kaiya, H.), pp. 93–107. Pergamon Press: Oxford.Google Scholar
Singh, M. M. & Kay, S. R. (1985). Pharmacology of central cholinergic mechanisms and schizophrenic disorders. In Central Cholinergic Mechanisms and Adaptive Dysfunctions (ed. Singh, M. M., Warburton, D. M. and Lal, H.), pp.247–308. Plenum Press: New York.CrossRefGoogle Scholar
Singh, M. M. & Smith, J. M. (1973). Sleeplessness in acute and chronic schizophrenia: Response to haloperidol and anti-Parkinsonism agents. Psychopharmacologia 29, 21–32.CrossRefGoogle ScholarPubMed
Singh, M. M., Kay, S. R. & Pitman, R. K. (1981 a). Aggression control and structuring of social relations among recently admitted schizophrenics: Psychiatry Research 5, 157–169.CrossRefGoogle ScholarPubMed
Singh, M. M., Kay, S. R. & Pitman, R. K. (1981 b). Territorial behavior of schizophrenics. A phylogenetic approach. Journal of Nervous and Mental Disease 169, 503–512.CrossRefGoogle ScholarPubMed
Slater, E. & Roth, M. (1969). Clinical Psychiatry. 3rd edn.Williams and Wilkins: Baltimore.Google Scholar
Spitzer, R. L., Endicott, J. & Cohen, M. S. (1969). Psychiatric Evaluation Form – R2. Manual of Instructions. State of New York, Department of Mental Hygiene: Albany.Google Scholar
Spitzer, R. L., Endicott, J. & Robins, E. (1978). Research Diagnostic Criteria (RDC) for a Selected Group of Functional Disorders. Biometrics Research, New York State Psychiatric Institute: New York.Google Scholar